Fosamprenavir

Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

Fosamprenavir Versus Other Protease Inhibitors

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Fosamprenavir Expanded Access

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks